Načítá se...

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab

BACKGROUND: Biomarkers are needed to estimate which patients benefit most from combination ipilimumab and nivolumab immunotherapy. Rigorous biomarker analyses from prior ipilimumab randomized studies without nivolumab are likely to inform which biomarker analyses should be prioritized when examining...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Melanoma Res
Hlavní autoři: Postow, Michael A., Chasalow, Scott D., Kuk, Deborah, Panageas, Katherine S., Cheng, Michael L., Yuan, Jianda, Wolchok, Jedd D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485135/
https://ncbi.nlm.nih.gov/pubmed/31425479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000633
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!